This presents a novel mechanism of intervention for FXS that may produce viable therapeutic alternatives to traditional gene therapy; however, this approach will not be suitable for every FXS patient as only a subpopulation has the FMR1-217 isoform required for the ASO-mediated rescue. This evidence concerns the gene FMR1 and fragile X syndrome.